# A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

Source: https://onco.cc/trials/nct06206837/  
OnCo record `nct06206837` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Vepdegestrant and Atirmociclib in advanced solid tumours, run by Pfizer, active and no longer recruiting.

## Summary

A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. is a phase 1/2 interventional study registered as NCT06206837 by Pfizer, with 71 participants enrolled, started 2024-02-19 and due to reach its primary completion in 2025-09-05. Interventions recorded: vepdegestrant and PF-07220060.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06206837
- Phase: 1/2
- Setting: AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT (ARV-471/PF-07850327), AN ORAL PROTEOLYSIS TARGETING CHIMERA, IN COMBINATION WITH PF-07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER
- Sponsor: Pfizer
- Enrolled: 71

## Sources

- ClinicalTrials.gov NCT06206837: https://clinicaltrials.gov/study/NCT06206837

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Atirmociclib](https://onco.cc/drugs/atirmociclib/), [Vepdegestrant](https://onco.cc/drugs/vepdegestrant/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct06206837.json